Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06613568

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

North America Research Institute, San Dimas, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are between 18 and 80 years of age and Care Partner is at least 18 years of age at the time of signing consent.
  • Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and be deemed stable by their treating nephrologist prior to the end of the Screening Period
  • Have a well-functioning and stable vascular access (tunneled central venous catheter arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min prior to the end of Screening
  • Can successfully complete a Skills and Comprehension Assessment with a Care Partner prior to the completion of the Training Period.

Exclusion criteria

  • Hgb level of < 9 g/dL at Screening
  • Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during the Run-In period defined as:
  • Persistent pre-dialysis sitting SBP < 100 mmHg despite medical therapy,
  • Nadir intradialytic Systolic Blood Pressure (SBP) < 90 mmHg, if Subject's pre-HD SBP < 160 mmHg
  • Nadir intradialytic SBP < 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg
  • Documented history of non-adherence to dialysis therapy that would prevent successful completion of the study
  • Participant had an average ultrafiltration rate > 13 mL/kg/hour during the last 2 weeks prior to Screening, per medical records.
  • Had a significant cardiovascular adverse event within the last 90 days prior to Screening.

Treatment and study plan

Moda-flx Hemodialysis System™

Device

The Moda-flx Hemodialysis System™ is a portable hemodialysis system

Primary outcomes

  1. Weekly Standardized Dialysis Adequacy

    Time frame: Up to 10 weeks per period

    Standardized weekly (stdKt/V) values as measured once every week during the Professional Care and At Home treatment settings

  2. Adverse Event (AE) Rate

    Time frame: Up to 10 weeks per period

    The adverse event (AE) rate: defined as the number of Study Emergent AEs per 100 dialysis treatments occurring in the At Home period of the study, compared with those occurring during the Professional Care period.

Secondary outcomes

  1. Goal Ultrafiltration Volume

    Time frame: Up to 10 weeks per period

    Compliance with fluid removal goals that are defined as:

    Ultrafiltration (net fluid removal), such that the recorded value from the Moda-flx Hemodialysis System™ is within ± 100 mL/h or ± 250 mL (whichever is less) of set point during the treatment, based on the UF prescription.

  2. Study Emergent Pre-Specified Adverse Events

    Time frame: Up to 10 weeks per period

    Study Emergent Pre-Specified Adverse Eventss, categorized by study period (Professional Care and At Home) severity, device relationship and procedure relationship. Study-emergent Pre-Specified AEs are those AEs with an onset on or after the date of first treatment during the Run-In Period, which will be comprised of any of the following:

    • A composite of:
    • Serious Adverse Event
    • Allergic Reaction
    • Blood Loss
    • Hemolytic Reaction
    • Infection
    • Intradialytic Event
    • Vascular Access Complication
    • Pyrogenic Reaction

Study contacts

Contact information is provided by the study sponsor or research team.

Michael Gastauer

CONTACT

[email protected]

949-916-5851

Sponsors and collaborators

Lead sponsor

Diality Inc.

Industry

Registry information

Official study title

Prospective, Non-Randomized, Multicenter, Open-Label Study Evaluating the Use of the Moda-flx Hemodialysis System™ Under Professional Care and At Home by Participants With End Stage Kidney Disease (ESKD) Who Are on Stable Dialysis Regimens

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Sep 26, 2024
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.